CYP2A13抗体—艾普蒂

The cytochrome P450 enzyme CYP2A13. primarily expressed in the respiratory tract (e.g., nasal mucosa, lungs), plays a critical role in metabolizing xenobiotics and endogenous compounds. It is notable for activating procarcinogens like tobacco-specific nitrosamines (e.g., NNK) and aflatoxin B1. contributing to tissue-specific toxicity and carcinogenesis, particularly in lung and nasal cancers. CYP2A13 antibodies are essential research tools for detecting and quantifying this enzyme in tissues, elucidating its expression patterns, and studying its role in disease mechanisms. Due to low systemic expression and genetic polymorphisms affecting enzyme activity (e.g., rs56113850 variant), these antibodies help explore interindividual susceptibility to chemical-induced pathologies. They are also used in drug metabolism studies, toxicology assessments, and investigations linking CYP2A13 polymorphisms to respiratory diseases like COPD or cancer risk. Commercially available CYP2A13 antibodies are typically developed in rabbits or mice, targeting specific epitopes (e.g., C-terminal regions). Validation includes Western blotting, immunohistochemistry, and enzyme activity assays. Research using these antibodies has advanced understanding of CYP2A13's dual role in detoxification and metabolic activation, informing strategies to mitigate chemical toxicity or develop targeted therapies.